Stocks and Investing Stocks and Investing
Fri, August 11, 2023
Thu, August 10, 2023

Justin Zelin Maintained (ACET) at Strong Buy with Decreased Target to $10 on, Aug 10th, 2023


Published on 2024-10-28 05:49:11 - WOPRAI, Justin Zelin
  Print publication without navigation


Justin Zelin of BTIG, Maintained "Adicet Bio, Inc." (ACET) at Strong Buy with Decreased Target from $20 to $10 on, Aug 10th, 2023.

Justin has made no other calls on ACET in the last 4 months.



There are 4 other peers that have a rating on ACET. Out of the 4 peers that are also analyzing ACET, 3 agree with Justin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Schmidt of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $20 on, Tuesday, June 27th, 2023
  • Reni Benjamin of "JMP Securities" Downgraded from Buy to Hold on, Tuesday, June 27th, 2023
  • Brian Cheng of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $6 on, Thursday, June 1st, 2023


This is the rating of the analyst that currently disagrees with Justin


  • Edward White of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $38 on, Tuesday, June 27th, 2023
Contributing Sources